Advertisement

Fall 34: Prävention – 72 Jahre, ♂, Prädiabetes, Übergewicht, grenzgradige Nüchternglukose, normaler oraler Glukosetoleranztest

  • Stefan Kopf
Chapter

Zusammenfassung

Ein 72-jähriger Patient mit grenzgradiger Nüchternglukose, normalem oralen Glukosetoleranztest, einem BMI von 38, einer gut eingestellten Hypertonie, nächtlichem Kribbeln seit 5 Jahren, kleinen Bulbusplaques und nicht bisher zum Infarkt führenden Koronarstenosen, fragt nach den Möglichkeiten der Diabetesprävention. Hat er nicht schon einen Diabetes „ohne Hyperglykämie“?

Literatur

  1. Callaghan BC, Xia R, Reynolds E, Banerjee M, Rothberg AE, Burant CF, Villegas-Umana E, Pop-Busui R, Feldman EL (2016) Association between metabolic syndrome components and polyneuropathy in an obese population. JAMA Neurol 73(12):1468–1476.  https://doi.org/10.1001/jamaneurol.2016.3745CrossRefPubMedPubMedCentralGoogle Scholar
  2. Diabetes Prevention Program Research G (2015) Long-term effects of lifestyle intervention or metformin on diabetes development and microvascular complications over 15-year follow-up: the Diabetes Prevention Program Outcomes Study. Lancet Diabetes Endocrinol 3(11):866–875.  https://doi.org/10.1016/S2213-8587(15)00291-0CrossRefGoogle Scholar
  3. Knowler WC, Barrett-Connor E, Fowler SE, Hamman RF, Lachin JM, Walker EA, Nathan DM, Diabetes Prevention Program Research G (2002) Reduction in the incidence of type 2 diabetes with lifestyle intervention or metformin. N Engl J Med 346(6):393–403.  https://doi.org/10.1056/NEJMoa012512CrossRefGoogle Scholar
  4. Li G, Zhang P, Wang J, An Y, Gong Q, Gregg EW, Yang W, Zhang B, Shuai Y, Hong J, Engelgau MM, Li H, Roglic G, Hu Y, Bennett PH (2014) Cardiovascular mortality, all-cause mortality, and diabetes incidence after lifestyle intervention for people with impaired glucose tolerance in the Da Qing Diabetes Prevention Study: a 23-year follow-up study. Lancet Diabetes Endocrinol 2(6):474–480.  https://doi.org/10.1016/S2213-8587(14)70057-9CrossRefPubMedGoogle Scholar
  5. Li G, Zhang P, Wang J, Gregg EW, Yang W, Gong Q, Li H, Li H, Jiang Y, An Y, Shuai Y, Zhang B, Zhang J, Thompson TJ, Gerzoff RB, Roglic G, Hu Y, Bennett PH (2008) The long-term effect of lifestyle interventions to prevent diabetes in the China Da Qing Diabetes Prevention Study: a 20-year follow-up study. Lancet 371(9626):1783–1789.  https://doi.org/10.1016/S0140-6736(08)60766-7CrossRefPubMedGoogle Scholar
  6. Perreault L, Pan Q, Mather KJ, Watson KE, Hamman RF, Kahn SE, Diabetes Prevention Program Research G (2012) Effect of regression from prediabetes to normal glucose regulation on long-term reduction in diabetes risk: results from the Diabetes Prevention Program Outcomes Study. Lancet 379(9833):2243–2251.  https://doi.org/10.1016/S0140-6736(12)60525-XCrossRefGoogle Scholar
  7. Tancredi M, Rosengren A, Svensson AM, Kosiborod M, Pivodic A, Gudbjornsdottir S, Wedel H, Clements M, Dahlqvist S, Lind M (2015) Excess mortality among persons with type 2 diabetes. N Engl J Med 373(18):1720–1732.  https://doi.org/10.1056/NEJMoa1504347CrossRefPubMedGoogle Scholar
  8. Task Force Members: Ryden L, Grant PJ, Anker SD, Berne C, Cosentino F, Danchin N, Deaton C, Escaned J, Hammes HP, Huikuri H, Marre M, Marx N, Mellbin L, Ostergren J, Patrono C, Seferovic P, Uva MS, Taskinen MR, Tendera M, Tuomilehto J, Valensi P, Zamorano JL, Guidelines ESCCfP, Zamorano JL, Achenbach S, Baumgartner H, Bax JJ, Bueno H, Dean V, Deaton C, Erol C, Fagard R, Ferrari R, Hasdai D, Hoes AW, Kirchhof P, Knuuti J, Kolh P, Lancellotti P, Linhart A, Nihoyannopoulos P, Piepoli MF, Ponikowski P, Sirnes PA, Tamargo JL, Tendera M, Torbicki A, Wijns W, Windecker S, Document R, De Backer G, Sirnes PA, Ezquerra EA, Avogaro A, Badimon L, Baranova E, Baumgartner H, Betteridge J, Ceriello A, Fagard R, Funck-Brentano C, Gulba DC, Hasdai D, Hoes AW, Kjekshus JK, Knuuti J, Kolh P, Lev E, Mueller C, Neyses L, Nilsson PM, Perk J, Ponikowski P, Reiner Z, Sattar N, Schachinger V, Scheen A, Schirmer H, Stromberg A, Sudzhaeva S, Tamargo JL, Viigimaa M, Vlachopoulos C, Xuereb RG (2013) ESC Guidelines on diabetes, pre-diabetes, and cardiovascular diseases developed in collaboration with the EASD: the Task Force on diabetes, pre-diabetes, and cardiovascular diseases of the European Society of Cardiology (ESC) and developed in collaboration with the European Association for the Study of Diabetes (EASD). Eur Heart J 34 (39): 3035–3087.  https://doi.org/10.1093/eurheartj/eht108
  9. Uusitupa M, Peltonen M, Lindstrom J, Aunola S, Ilanne-Parikka P, Keinanen-Kiukaanniemi S, Valle TT, Eriksson JG, Tuomilehto J, Finnish Diabetes Prevention Study G (2009) Ten-year mortality and cardiovascular morbidity in the Finnish Diabetes Prevention Study–secondary analysis of the randomized trial. PloS one 4(5):e5656.  https://doi.org/10.1371/journal.pone.0005656CrossRefGoogle Scholar

Copyright information

© Springer-Verlag GmbH Deutschland, ein Teil von Springer Nature 2018

Authors and Affiliations

  1. 1.Abteilung Innere Medizin IMedizinische UniversitätsklinikHeidelbergDeutschland

Personalised recommendations